SCHEMBL14764633

SCHEMBL14764633

Cc1nc2c(Br)cccc2nc1NN

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 3/20 0.41
POLB P06746 1/20 0.41
RAB9A P51151 1/20 0.41
BACE1 P56817 2/20 0.36
CRHR1 P34998 2/20 0.36
NSD2 O96028 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PKMYT1 Q99640 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
LCK P06239 1/20 0.33
NQO2 P16083 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14764541 0.93 ALDH1A1 (0.37) MAPTALDH1A1KDM4EPOLBRAB9A
SCHEMBL14764362 0.83 MAPT (0.42) MAPTALDH1A1KDM4EPOLBRAB9A
SCHEMBL14764490 0.80 ALDH1A1 (0.41) MAPTALDH1A1KDM4EPOLBRAB9A
SCHEMBL30217623 0.80 MAPT (0.44) MAPTALDH1A1KDM4EBACE1PKMYT1
SCHEMBL2513088 0.80 MAPT (0.44) MAPTALDH1A1KDM4EBACE1PKMYT1
SCHEMBL14764689 0.78 NQO2 (0.56) MAPTALDH1A1KDM4EPOLBRAB9A
SCHEMBL27763044 0.77 TDP1 (0.41) MAPTALDH1A1POLBRAB9ABACE1
SCHEMBL12503018 0.76 MAPT (0.58) MAPTALDH1A1KDM4EPOLBRAB9A
SCHEMBL14764430 0.76 MAPT (0.41) MAPTALDH1A1KDM4EPOLBRAB9A
SCHEMBL15230796 0.74 PIM1 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013034755-A1 TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS H. LUNDBECK A/S (DK) 2013-03-14 WO disclosed
WO-2013034755-A1 TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS H. LUNDBECK A/S (DK) 2013-03-14 WO disclosed